These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25693652)

  • 21. Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects.
    Woodley WD; Yue W; Morel DR; Lainesse A; Pettis RJ; Bolick NG
    Clin Transl Sci; 2021 May; 14(3):859-869. PubMed ID: 33278331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study.
    Jen J; LaBadie RR; Liang Y; Crownover PH; Gao X; Hey-Hadavi JH
    Growth Horm IGF Res; 2013 Aug; 23(4):114-9. PubMed ID: 23651793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
    Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
    BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid growth hormone: preservatives and buffers.
    Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
    Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components.
    Kinnunen HM; Sharma V; Contreras-Rojas LR; Yu Y; Alleman C; Sreedhara A; Fischer S; Khawli L; Yohe ST; Bumbaca D; Patapoff TW; Daugherty AL; Mrsny RJ
    J Control Release; 2015 Sep; 214():94-102. PubMed ID: 26210441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pain perception during miniscrew placement in orthodontic patients with a visual analog scale survey between compound topical and needle-injected anesthetics: A crossover, prospective, randomized clinical trial.
    Lamberton JA; Oesterle LJ; Shellhart WC; Newman SM; Harrell RE; Tilliss T; Singh N; Carey CM
    Am J Orthod Dentofacial Orthop; 2016 Jan; 149(1):15-23. PubMed ID: 26718373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation.
    Halpern V; Wheeless A; Brache V; Lendvay A; Cochón L; Taylor D; Dorflinger LJ
    Contracept X; 2023; 5():100100. PubMed ID: 37823034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
    Xu Z; Wang Q; Zhuang Y; Frederick B; Yan H; Bouman-Thio E; Marini JC; Keen M; Snead D; Davis HM; Zhou H
    J Clin Pharmacol; 2010 Mar; 50(3):276-84. PubMed ID: 19940229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
    Thomas JR; Yocum RC; Haller MF; Flament J
    J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
    Heise T; Nosek L; Dellweg S; Zijlstra E; Præstmark KA; Kildegaard J; Nielsen G; Sparre T
    Diabetes Obes Metab; 2014 Oct; 16(10):971-6. PubMed ID: 24720741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.
    Ng P; Incekol D; Lee R; Paisley E; Dara C; Brandle I; Kaufman M; Chen C; Trudel S; Tiedemann R; Reece D; Kukreti V
    J Oncol Pharm Pract; 2015 Aug; 21(4):285-92. PubMed ID: 24781451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
    Xu Z; Marciniak SJ; Frederick B; Kim L; Zhuang Y; Davis HM; Zhou H
    Clin Ther; 2015 Feb; 37(2):427-38. PubMed ID: 25438720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
    Sieber CC; Beglinger C; Bart S; Tschoepl M; Currie G; Larsen F; Drewe J
    Clin Pharmacol Ther; 2004 Jan; 75(1):70-9. PubMed ID: 14749693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.
    Kokolakis G; Kreis G; Falqués M; Aparici M; Sondermann W
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2135-2144. PubMed ID: 35984626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.